Papers
Topics
Authors
Recent
Assistant
AI Research Assistant
Well-researched responses based on relevant abstracts and paper content.
Custom Instructions Pro
Preferences or requirements that you'd like Emergent Mind to consider when generating responses.
Gemini 2.5 Flash
Gemini 2.5 Flash 165 tok/s
Gemini 2.5 Pro 57 tok/s Pro
GPT-5 Medium 39 tok/s Pro
GPT-5 High 37 tok/s Pro
GPT-4o 106 tok/s Pro
Kimi K2 185 tok/s Pro
GPT OSS 120B 445 tok/s Pro
Claude Sonnet 4.5 37 tok/s Pro
2000 character limit reached

Adjusting for Ascertainment Bias in Meta-Analysis of Penetrance for Cancer Risk (2402.15030v1)

Published 23 Feb 2024 in stat.ME

Abstract: Multi-gene panel testing allows efficient detection of pathogenic variants in cancer susceptibility genes including moderate-risk genes such as ATM and PALB2. A growing number of studies examine the risk of breast cancer (BC) conferred by pathogenic variants of such genes. A meta-analysis combining the reported risk estimates can provide an overall age-specific risk of developing BC, i.e., penetrance for a gene. However, estimates reported by case-control studies often suffer from ascertainment bias. Currently there are no methods available to adjust for such ascertainment bias in this setting. We consider a Bayesian random-effects meta-analysis method that can synthesize different types of risk measures and extend it to incorporate studies with ascertainment bias. This is achieved by introducing a bias term in the model and assigning appropriate priors. We validate the method through a simulation study and apply it to estimate BC penetrance for carriers of pathogenic variants of ATM and PALB2 genes. Our simulations show that the proposed method results in more accurate and precise penetrance estimates compared to when no adjustment is made for ascertainment bias or when such biased studies are discarded from the analysis. The estimated overall BC risk for individuals with pathogenic variants in (1) ATM is 5.77% (3.22%-9.67%) by age 50 and 26.13% (20.31%-32.94%) by age 80; (2) PALB2 is 12.99% (6.48%-22.23%) by age 50 and 44.69% (34.40%-55.80%) by age 80. The proposed method allows for meta-analyses to include studies with ascertainment bias resulting in a larger number of studies included and thereby more robust estimates.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (64)
  1. Breast cancer risk in women from Ghana carrying rare germline pathogenic mutations. Cancer Epidemiology, Biomarkers & Prevention, 31:1593–1601.
  2. ATM mutations in Finnish breast cancer patients. Journal of Medical Genetics, 39(3):192–196.
  3. Ataxia-telangiectasia genes and breast cancer risk in a French family study. Journal of Dairy Research, 72(S1):73–80.
  4. Breast-cancer risk in families with mutations in PALB2. The New England Journal of Medicine, 371(6):497–506.
  5. The cost-effectiveness of multigene panel testing for hereditary breast and ovarian cancer in Norway. MDM policy & practice, 4(1):2381468318821103.
  6. Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. Journal of Cancer Research and Clinical oncology, 144:2495–2513.
  7. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations. Clinical Genetics, 73(5):465–473.
  8. Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. Cancer Medicine, 7(1):46–55.
  9. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncology, 3(9):1190–1196.
  10. Coughlin, S. S. (1990). Recall bias in epidemiologic studies. Journal of Clinical Epidemiology, 43(1):87–91.
  11. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. The Lancet Oncology, 16(6):638–644.
  12. NCCN guidelines insights: genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. Journal of the National Comprehensive Cancer Network, 15(1):9–20.
  13. Validation of a semiautomated natural language processing–based procedure for meta-analysis of cancer susceptibility gene penetrance. JCO Clinical Cancer Informatics, 3:1–9.
  14. Meta-analysis in clinical trials. Controlled Clincal Trials, 7(3):177–188.
  15. Evaluating breast cancer predisposition genes in women of african ancestry. Genetics in Medicine, 24(7):1468–1475.
  16. Breast cancer risk genes-association analysis in more than 113,000 women. The New England journal of medicine, 384(5):428–439.
  17. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families? Oncotarget, 8:1957 – 1971.
  18. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clinical Cancer Research, 14(14):4667–4671.
  19. Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Research and Treatment, 193(2):485–494.
  20. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nature Genetics, 15(3):307–310.
  21. On the bias of various estimators of the logit and its variance with application to quantal bioassay. Biometrika, 54:181–187.
  22. Bayesian Data Analysis. Chapman and Hall/CRC, third edition.
  23. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 144(8):1962–1974.
  24. BRCA phenocopies or ascertainment bias? Journal of Medical Genetics, 44(8):e86–e86.
  25. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Research, 13(4):1–9.
  26. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Breast Cancer Research and Treatment, 128:573–579.
  27. Haldane, J. (1956). The estimation and significance of the logarithm of a ratio of frequencies. Annals of Human Genetics, 20(4):309–311.
  28. Harewood, G. (2005). Assessment of publication bias in reporting eus performance in staging rectal cancer. Gastrointestinal Endoscopy, 61(5):AB280.
  29. Gene panel testing of 5589 BRCA 1/2-negative index patients with breast cancer in a routine diagnostic setting: Results of the German consortium for hereditary breast and ovarian cancer. Cancer Medicine, 7(4):1349–1358.
  30. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clinical Cancer Research, 15(9):3214–3222.
  31. Interpretation of epidemiologic studies very often lacked adequate consideration of confounding. Journal of Clinical Epidemiology, 93:94–102.
  32. A population-based study of genes previously implicated in breast cancer. New England Journal of Medicine, 384(5):440–451.
  33. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes, Chromosomes and Cancer, 26(4):286–294.
  34. Bias and efficiency in family-based gene-characterization studies: Conditional, prospective, retrospective, and joint likelihoods. The American Journal of Human Genetics, 66(3):1119–1131.
  35. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer. Genetic Testing, 4(4):403–407.
  36. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precision Oncology, 1(1):1–12.
  37. Clinvar: improving access to variant interpretations and supporting evidence. Nucleic Acids Research, 46(D1):D1062–D1067.
  38. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Journal of Medical Genetics, 53(1):34–42.
  39. A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value in Health, 20(4):547–555.
  40. ATM gene mutations in sporadic breast cancer patients from Brazil. Springerplus, 4(1):1–10.
  41. Penetrance of ATM gene mutations in breast cancer: A meta-analysis of different measures of risk. Genetic Epidemiology, 40(5):425–431.
  42. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nature Communications, 9(1):1–7.
  43. Pathogenic variant spectrum in breast cancer risk genes in Finnish patients. Cancers, 14(24):6158.
  44. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. British Journal of Cancer, 93(2):260–265.
  45. What’s new in genetic testing for cancer susceptibility? Oncology (Williston Park, N.Y.), 30(9):787–799.
  46. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis, 28(5):1040–1045.
  47. R Core Team (2020). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
  48. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 39(2):165–167.
  49. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 38(8):873–875.
  50. Adjusting trial results for biases in meta-analysis: Combining data-based evidence on bias with detailed trial assessment. Journal of the Royal Statistical Society. Series A,(Statistics in Society), 183(1):193–209.
  51. Bayesian meta-analysis of penetrance for cancer risk. Biometrics. In press, https://arxiv.org/abs/2304.01912.
  52. Meta-analysis of breast cancer risk for individuals with PALB2 pathogenic variants. Under review, https://www.medrxiv.org/content/10.1101/2023.05.31.23290791v1.
  53. Contribution of mutations in ATM to breast cancer development in the Czech population. Oncology Reports, 19(6):1505–1510.
  54. Cancer stat facts: Female breast cancer. Available at:. https://seer.cancer.gov/statfacts/html/breast.html. [accessed February 28, 2022].
  55. Sutton-Tyrrell, K. (1991). Assessing bias in case-control studies. proper selection of cases and controls. Stroke, 22(7):938–942.
  56. Breast cancer incidence and the effect of cigarette smoking in heterozygous carriers of mutations in the ataxia-telangiectasia gene. Cancer Epidemiology and Prevention Biomarkers, 17(11):3188–3192.
  57. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer: Interdisciplinary International Journal of the American Cancer Society, 92(3):479–487.
  58. Cancer risks and mortality in heterozygous ATM mutation carriers. Journal of the National Cancer Institute, 97(11):813–822.
  59. Panel testing for familial breast cancer: Calibrating the tension between research and clinical care. Journal of Clinical Oncology, 34(13):1455–1459.
  60. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Research, 63(12):3325–3333.
  61. Genetic predisposition to breast cancer: Past, present, and future. Annual Review of Genomics and Human Genetics, 9:321–345.
  62. Bias modelling in evidence synthesis. Journal of the Royal Statistical Society: Series A (Statistics in Society), 172(1):21–47.
  63. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences, 107(28):12629–12633.
  64. Inherited breast cancer in Nigerian women. Journal of Clinical Oncology, 36(28):2820–2825.
Citations (1)

Summary

We haven't generated a summary for this paper yet.

Dice Question Streamline Icon: https://streamlinehq.com

Open Problems

We haven't generated a list of open problems mentioned in this paper yet.

Lightbulb Streamline Icon: https://streamlinehq.com

Continue Learning

We haven't generated follow-up questions for this paper yet.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

X Twitter Logo Streamline Icon: https://streamlinehq.com

Tweets

This paper has been mentioned in 1 tweet and received 0 likes.

Upgrade to Pro to view all of the tweets about this paper: